Glass House today announced the completion of its first international sale of smokeable CBD biomass to Europe.
The product sold was part of the initial commercial harvest of Greenhouse 4 of the company’s Camarillo Farm. This greenhouse was initially planted for commercial hemp in winter 2025.
All hemp biomass produced in Greenhouse 4 is fully compliant with California regulations and will remain sellable under the proposed federal intoxicating hemp ban. While initial sales are focused on European distribution, longer term, Greenhouse 4 production is being positioned for supply into the proposed federal Medicare reimbursable CBD program.
“We are very pleased with our team’s initial harvest and early sales with commercial hemp,” said Kyle Kazan, co-founder, chairman and CEO of Glass House, in a statement. “Our initial hemp sale to Europe is a historic step for the company as it reflects the first sale of any Glass House product outside our home state of California. We will continue to develop this product line and plan to use initial sales experiences for both R&D and brand development ahead of anticipated near-term medical cannabis sales into Europe. To be clear, we will compliantly grow whatever cannabis and hemp that we can sell for the highest price as the legal channels continue to open for us.”
“Furthermore, given our experience as a leading scaled producer of quality cannabis and our on-going collaborative relationship with UC Berkeley on the development of cannabinoids for novel medical products, Glass House is uniquely qualified to participate in the growth opportunities ahead for the US CBD market including any reimbursable Medicare program as was proposed by President Trump last December. We anticipate that any reimbursable program will lead to CBD product development from both traditional CPG and pharma and we welcome the opportunity to supply these new addressable markets with product from Greenhouse 4.”
